TIGIT-based immunotherapeutics in lung cancer
Patel, Akshay J Middleton, Gary W
Patel, Akshay J
Middleton, Gary W
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-05-26
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by the advent of PD-1/PD-L1 checkpoint blockade immunotherapy. We explore the murine data underlying TIGIT blockade and further explore the reliance of effective anti-TIGIT therapy on DNAM-1(CD226)-positive activated effector CD8+ T cells. The synergism with anti-PD-1 therapy is also explored. Future directions in the realm of overcoming resistance to checkpoint blockade and extending the repertoire of other checkpoints are also briefly explored.
Citation
Patel AJ, Middleton GW. TIGIT-based immunotherapeutics in lung cancer. Immunother Adv. 2023 May 26;3(1):ltad009. doi: 10.1093/immadv/ltad009
Type
Article